- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers
Panelists discuss how effective communication about amyloid-targeting therapies requires transparent discussions of modest cognitive benefits alongside potential risks, particularly events related to amyloid-related imaging abnormalities (ARIA), while addressing practical considerations including treatment burden, infusion center logistics, monitoring requirements, costs, insurance coverage, and caregiver involvement to help patients and families make fully informed decisions aligned with their values and circumstances.
EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease
EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection
EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment
EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help
EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease
EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease
EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas
EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations
EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy
EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations
EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease
EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers
EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy
EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA
EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies
EP: 16.Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations
EP: 17.Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies
EP: 18.Final Thoughts Alzheimer Disease Care
Video content above is prompted by the following:
- How do you discuss the risk-benefit profile of the amyloid-targeting therapies with patients and their caregivers, including adverse event considerations, adherence to treatment, travel to the infusion center, etc?
Echocardiographic Assessment Shows Promise as Risk Predictor in PAH
August 29th 2025Close to 40% of patients with right heart failure and pulmonary arterial hypertension (PAH) who remain critically ill and require admittance to the intensive care unit die within 1 year of that hospitalization.
Read More
Missed Opportunities for Salpingectomy Highlight Gaps in Ovarian Cancer Prevention
August 27th 2025Many patients later diagnosed with high-grade serous cancer had prior surgical or genetic testing opportunities that could have reduced their ovarian cancer risk, underscoring the need to expand opportunistic salpingectomy and preventive strategies.
Read More
